Pembrolizumab + Investigational Agents for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores new treatments for individuals with certain types of non-small cell lung cancer that can be surgically removed. Researchers are testing the effectiveness of pembrolizumab (an immunotherapy drug) combined with other drugs to shrink or eliminate cancer before and after surgery. Participants should have untreated non-small cell lung cancer that is operable. The trial aims to determine if these treatments can eliminate cancer cells in tumors and lymph nodes. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer treatment.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or systemic steroids, you may need to stop or adjust them before starting the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that pembrolizumab is generally well-tolerated by patients. The FDA has already approved it for treating other types of cancer, providing strong safety evidence. Common side effects include tiredness, nausea, and skin rash, but these are usually manageable.
Sacituzumab tirumotecan is newer and has been tested in smaller groups. Early studies indicate it is also generally well-tolerated, though some patients have experienced side effects like low blood counts and diarrhea, which were mostly mild to moderate.
This trial combines pembrolizumab with sacituzumab tirumotecan. Early research suggests that the combination is safe for most people. The trial is in Phase 2, indicating some evidence of safety, but researchers continue to gather more data. Potential risks should always be discussed with the study team before joining.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these lung cancer treatments because they combine pembrolizumab, a well-known immunotherapy, with either a novel investigational agent or with platinum-based chemotherapy. The first treatment arm introduces sacituzumab tirumotecan, aiming to enhance the immune response against cancer cells, potentially offering a new mechanism for tackling tumors. The second arm uses a traditional platinum-based chemotherapy regimen alongside pembrolizumab, which is already a standard treatment, but the combination may improve patient outcomes by leveraging both immunotherapy and chemotherapy benefits. These approaches offer promising new ways to enhance the effectiveness of treatment before and after surgery in lung cancer patients.
What evidence suggests that this trial's treatments could be effective for lung cancer?
This trial studies two different treatment combinations for non-small-cell lung cancer (NSCLC). One arm combines pembrolizumab with sacituzumab tirumotecan, which previous studies have shown to improve survival rates by more effectively targeting cancer cells. Research suggests that adding sacituzumab tirumotecan to pembrolizumab after surgery could help remove more cancer cells. Another arm explores pembrolizumab combined with platinum-based chemotherapy, which is under investigation for its potential to shrink tumors before surgery. This trial explores both combinations to determine if they can reduce or eliminate cancer cells in tumors and lymph nodes, leading to better patient outcomes.12346
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for individuals with resectable non-small cell lung cancer. Participants should be suitable for surgery and have not received prior systemic therapy for their lung cancer. Specific details on inclusion or exclusion criteria are not provided.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants receive pembrolizumab and chemotherapy prior to surgery
Surgery
Participants undergo surgical resection of the tumor
Adjuvant Treatment
Participants receive pembrolizumab post-surgery for 13 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pembrolizumab
Trial Overview
The study tests Pembrolizumab combined with other agents like Cisplatin, Carboplatin, Gemcitabine, etc., before (neoadjuvant) and after (adjuvant) surgery. The aim is to see if the treatment clears cancer cells from tumors and lymph nodes during surgery.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Neoadjuvant: Prior to surgery pembrolizumab 200 mg Q3W for 4 cycles (each cycle is 21 days); sacituzumab tirumotecan 4 mg/kg Q2W for 6 cycles (each cycle is 14 days), followed by surgery. Adjuvant: After surgery pembrolizumab 200 mg Q3W for 13 cycles (each cycle is 21 days). Optional adjuvant platinum-based doublet chemotherapy up to 4 cycles may be given at the investigator's discretion.
Neoadjuvant: Prior to surgery pembrolizumab 200 mg every three weeks (Q3W) for 4 cycles (each cycle is 21 days); Cisplatin 75 mg/m\^2 Q3W with gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 Q3W (squamous tumors), pemetrexed 500 mg/m\^2 Q3W (nonsquamous tumors), or paclitaxel 175 mg/m\^2 or 200 mg/m\^2 q3w (any histology) OR Carboplatin AUC 5 mg/mL• min or AUC 6 mg/mL• min with paclitaxel 175 mg/m\^2 or 200 mg/m\^2 Q3W (any histology), pemetrexed 500 mg/m\^2 Q3W (nonsquamous tumors), or gemcitabine 1000 mg/m\^2 on Day 1 and Day 8 Q3W (squamous tumors); followed by surgery. Adjuvant: After surgery pembrolizumab 200 mg Q3W for 13 cycles (each cycle is 21 days).
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
NCT06312137 | A Study to Assess Efficacy and Safety of ...
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving ...
P4.11D.02 Phase 3 Trofuse-007 Study
The TroFuse-007 study will evaluate the efficacy and safety of the addition of sac-TMT to pembrolizumab vs pembrolizumab alone in patients with previously ...
Recent advances in therapeutic strategies for non-small cell ...
Both targeted therapy and immunotherapy have significantly improved the survival of patients with metastatic non-small-cell lung cancer (NSCLC).
4.
uclahealth.org
uclahealth.org/clinical-trials/study-assess-efficacy-and-safety-pembrolizumab-with-orA Study to Assess Efficacy and Safety of Pembrolizumab ...
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving ...
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and ...
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in ...
Clinical Trials
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.